



# DIAGNOS

Your Knowledge Partner

**PRESS RELEASE**

OTCQB: DGNOF  
TSXV: ADK  
SOURCE: DIAGNOS Inc.

2018.01.25

## Arrowhead Business and Investment Decisions Initiates Analyst Coverage of DIAGNOS

Brossard, Quebec, Canada – January 25<sup>th</sup>, 2018 - DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its *FLAIRE* platform based on Artificial Intelligence (AI), announces the initiation of analyst coverage by Arrowhead Business and Investment Decisions, LLC (“ABID” or “Arrowhead”).

Arrowhead’s analyst coverage of DIAGNOS is available on the [ABID](#) website. Interested parties are invited to download the report and subscribe to updates on DIAGNOS’ ABID profile page at the following link [www.abid.co/TSXV.ADK](http://www.abid.co/TSXV.ADK) or to download the report directly by clicking [here \(http://abid.co/pdf/n/5822\)](http://abid.co/pdf/n/5822). Please feel free to direct any questions regarding the report by email to the lead analyst for Arrowhead on DIAGNOS, Parvati Rai; [parvati.ra@arrowheadbid.com](mailto:parvati.ra@arrowheadbid.com).

The Corporation is not responsible for the content, accuracy or timelines contained in analyst reports. Fees paid by the Corporation to ABID for investor relations and marketing services did not influence the opinion provided in the independent report. In addition, readers should be aware, and are cautioned, that opinions, estimates, or forecasts contained in the report only reflect the analyst’s view of the Corporation. The Corporation does not imply or in any way represent that any of the content, opinions, estimates, forward looking statements or forecasts regarding DIAGNOS made by the analyst accurately reflects or represents the opinions or beliefs of the Corporation and its management representatives. Before investing, consider your individual circumstances and investment time horizon and all risks associated with investing in DIAGNOS by speaking to your financial advisor and by accessing the Corporation’s public corporate disclosure.

### About Arrowhead

Arrowhead is a private New York City-based financial services firm, which provides buy-side advisory and corporate access services and disseminates targeted corporate information and analysis to its investor network, which is comprised of institutional investment funds, family offices and individuals. Arrowhead organizes two-way communications between this network and the issuers it represents. Arrowhead also advises public companies on investor relations, financial communications and capital markets strategies, helping them develop market awareness, gain exposure to qualified investors and enhance the accurate perception of their fair value.

Additional information on Arrowhead is available at [www.abid.co](http://www.abid.co), Arrowhead’s proprietary investor platform, and at [www.arrowheadbid.com](http://www.arrowheadbid.com).

### About DIAGNOS and its technologies

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging, text and traditional data mining. DIAGNOS has developed its own Artificial Intelligence (“AI”) technologies, *CARA* and *FLAIRE*. *FLAIRE* is a powerful AI engine that provides the capability of analyzing large and complex data sets. Using Deep Learning methodology combined with our own proprietary algorithms we can deploy rapidly new solutions to the healthcare market



# DIAGNOS

Your Knowledge Partner

**PRESS RELEASE**

OTCQB: DGNOF  
TSXV: ADK  
SOURCE: DIAGNOS Inc.

Additional information on DIAGNOS is available at [www.diagnos.ca](http://www.diagnos.ca) and [www.sedar.com](http://www.sedar.com).

For further information, please contact:

Mr. André Larente, President  
DIAGNOS Inc.  
Tel: 450-678-8882 ext. 224  
[alarente@diagnos.ca](mailto:alarente@diagnos.ca)

Daniel Renaud or Thomas Renaud, Managing Directors  
Arrowhead Business and Investment Decisions, LLC  
Tel: +1 212 619 6889, ext. 7010  
[diagnos@arrowheadbid.com](mailto:diagnos@arrowheadbid.com)

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*